云顶新耀医药科技有限公司 EVEREST MEDICINES
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023 2024-03-28 07:01
Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients 2024-03-20 09:16
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer 2024-03-18 09:00
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® 2024-03-12 09:28
Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau 2024-03-11 09:00
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024 2024-03-06 08:59
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis 2024-02-27 07:14
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis 2024-02-22 08:59
Everest Medicines' Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine 2024-02-21 09:00
Everest Medicines Announces Termination of Collaboration Agreements with Providence 2024-02-19 08:20
Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million 2024-01-22 07:50
Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline 2023-12-21 10:30
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China 2023-12-04 08:58
Everest Medicines Announces Positive Topline Results from Induction Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderate-to-Severe Active Ulcerative Colitis 2023-12-01 07:33
Everest Medicines Announces Acceptance of Nefecon® New Drug Applications for the Treatment of Primary IgA Nephropathy in Adult Patients in South Korea 2023-11-30 07:25
Everest Medicines Announces China NMPA's Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients 2023-11-24 12:54
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy 2023-10-27 13:45
Everest Medicines Announces Poster Presentation at ASN Kidney Week on Nefecon® Chinese Patient Data and to Hold Conference Calls 2023-10-27 08:22
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis 2023-10-16 07:48
Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023 2023-10-05 07:33
1 2 3 4 5 7